DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 1 Christopher Romig - 1 Stella - 1 Shaheen Lakhan - 1 Daniel Rimm - 1 Haig Goenjian - 1 Zac Imel - 1 Michael Tanana - 1
Top related locs:
Tanana
Top related orgs:
Therapeutics - 2 Click Therapeutics - 2 Food and Drug Administration - 2 Service - 1 Weber Human Services - 1 CNN - 1 Otsuka Pharmaceutical - 1 Gallup - 1

Search resuls for: "Click Therapeutics"


2 mentions found


☆ Mental-health professionals explore AI-powered digital therapeutics to treat patients and improve care
  + stars: | 2024-04-29 | by ( Christine Macintyre | ) www.businessinsider.com   time to read: +8 min
The fusion of human ingenuity and machine intelligence is offering an innovative approach to personalized mental-health care. They can also use AI to assess the quality of their services and find ways to improve as providers of mental-health care. As technology becomes more involved in mental-health care, ensuring data security, confidentiality, and equitable access to services must be top priorities. How an AI platform is helping mental-health-care providers improve their servicesThe AI platform Lyssn is another tech-driven tool for mental-health services. Lyssn aims to hold providers accountable for improved care, especially because "the quality of mental-health care is highly variable," Imel said.
Persons: —, Christopher Romig, Stella, Shaheen Lakhan, Daniel Rimm, Haig Goenjian, Zac Imel, Michael Tanana, Imel, Darin Carver, Carver, It's Organizations: Service, Therapeutics, Click Therapeutics, Food and Drug Administration, Weber Human Services Locations: Tanana
☆ FDA clears first digital treatment for depression, but experts caution that research is still early
  + stars: | 2024-04-02 | by ( Mira Cheng | ) edition.cnn.com   time to read: +5 min
CNN —The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder. About 18% of American adults – more than 1 in 6 – say they are depressed or receiving treatment for depression, a 2023 Gallup report found. Rejoyn is designed to serve as an adjunct to antidepressants for these partial responders, according to the news release. They were assigned to use either the Rejoyn app or a sham app that gave memory tasks that did not involve cognitive-emotional training or cognitive behavioral therapy. There is also the question of how engaged patients will be with the app, Torous said.
Persons: Rejoyn, Dr, John Kraus, Otsuka, Brian Iacoviello, John Torous, Torous, ”, ” Otsuka, Sanjay Gupta, “, ” Torous Organizations: CNN, Food and Drug Administration, Otsuka Pharmaceutical, Therapeutics, Gallup, Research, Click Therapeutics, Digital Psychiatry, Beth Israel Deaconess Medical, FDA, ” Otsuka Pharmaceutical, CNN Health
0 next >>
Total: 2